BioSyent Inc

RX-X

Analysis and Opinions about RX-X

Signal
Opinion
Expert
PAST TOP PICK
PAST TOP PICK
April 12, 2018

(A Top Pick March 29/17, Up 33%) They license health care products from outside of Canada. They have been very good at providing consistent return on equity as well as earnings growth. This year will be an interesting time. They are sitting on almost $20 Million as a war chest and adding to it every quarter. They are searching for opportunities and will be diligent in deploying it. They are an under the radar company.

Show full opinionHide full opinion
BioSyent Inc (RX-X)
April 12, 2018

(A Top Pick March 29/17, Up 33%) They license health care products from outside of Canada. They have been very good at providing consistent return on equity as well as earnings growth. This year will be an interesting time. They are sitting on almost $20 Million as a war chest and adding to it every quarter. They are searching for opportunities and will be diligent in deploying it. They are an under the radar company.

PAST TOP PICK
PAST TOP PICK
July 10, 2017

(A Top Pick July 4/16. Up 4.26%.) They in-license products from companies that don’t have a marketing presence of pharmaceutical products in Canada. A very, very well-run company. A nice ROE at just under 30%. Have 2 new cardiology products that should be coming online towards the end of 2018-2019. No debt and about $14 million in cash.

Show full opinionHide full opinion
BioSyent Inc (RX-X)
July 10, 2017

(A Top Pick July 4/16. Up 4.26%.) They in-license products from companies that don’t have a marketing presence of pharmaceutical products in Canada. A very, very well-run company. A nice ROE at just under 30%. Have 2 new cardiology products that should be coming online towards the end of 2018-2019. No debt and about $14 million in cash.

TOP PICK
TOP PICK
March 29, 2017

A pharma company, but not one that does research and trials. They license products. Their CEO is excellent and they are a very well run company. Growth will come from their existing product suite plus additionally 3 more products. They are active on the business development front. (Analysts’ target: $9.13).

Show full opinionHide full opinion
BioSyent Inc (RX-X)
March 29, 2017

A pharma company, but not one that does research and trials. They license products. Their CEO is excellent and they are a very well run company. Growth will come from their existing product suite plus additionally 3 more products. They are active on the business development front. (Analysts’ target: $9.13).

PAST TOP PICK
PAST TOP PICK
January 24, 2017

(A Top Pick July 4/16. Down 10.97%.) This in-licenses products and solutions from companies that are generally situated in Europe. They generally bring in in-licenses for companies that don’t want to set up their own sales force. A very consistent ROE generator. EPS has flatlined here, but he is optimistic that they are going to be getting back to a growth phase.

Show full opinionHide full opinion
BioSyent Inc (RX-X)
January 24, 2017

(A Top Pick July 4/16. Down 10.97%.) This in-licenses products and solutions from companies that are generally situated in Europe. They generally bring in in-licenses for companies that don’t want to set up their own sales force. A very consistent ROE generator. EPS has flatlined here, but he is optimistic that they are going to be getting back to a growth phase.

HOLD
HOLD
October 20, 2016

A bit tricky, because there is not necessarily a catalyst for earnings to really move in the near future. $9-$10 would be his more immediate target price. Extremely well-run. Very consistent ROE generator, and have been growing their earnings fabulously over the last 5 years or so. Have some new products they are going to be launching towards the end of 2017, which will be the impetus to see earnings and subsequently the stock to move higher. He likes this for the long-term.

Show full opinionHide full opinion
BioSyent Inc (RX-X)
October 20, 2016

A bit tricky, because there is not necessarily a catalyst for earnings to really move in the near future. $9-$10 would be his more immediate target price. Extremely well-run. Very consistent ROE generator, and have been growing their earnings fabulously over the last 5 years or so. Have some new products they are going to be launching towards the end of 2017, which will be the impetus to see earnings and subsequently the stock to move higher. He likes this for the long-term.

PAST TOP PICK
PAST TOP PICK
August 19, 2016

(A Top Pick July 4/16. Up 0.61%.) He still likes this. Recently came out with Q2 results which were quite good. Top line growth was about 17%. Very consistent ROE generators. Just announced 2 cardiology products they are going to be launching in Q3, which at peak revenue generation should increase revenues by 60%. Excellent management.

Show full opinionHide full opinion
BioSyent Inc (RX-X)
August 19, 2016

(A Top Pick July 4/16. Up 0.61%.) He still likes this. Recently came out with Q2 results which were quite good. Top line growth was about 17%. Very consistent ROE generators. Just announced 2 cardiology products they are going to be launching in Q3, which at peak revenue generation should increase revenues by 60%. Excellent management.

TOP PICK
TOP PICK
July 4, 2016

A small growth company, very consistent ROE generator. They recently announced licensing of two cardiology products that should increase revenue by 60% and they recently broke out of a trading range.

Show full opinionHide full opinion
BioSyent Inc (RX-X)
July 4, 2016

A small growth company, very consistent ROE generator. They recently announced licensing of two cardiology products that should increase revenue by 60% and they recently broke out of a trading range.

BUY
BUY
March 7, 2016

Had been built around a single product that related to iron deficiency. They have taken fairly high levels of profitability and have been picking up other stuff, and a lot of those other drugs have taken time to get a sales channel. Now that we are into 2016, those other products are starting to contribute, so the dependency on a single drug is getting smaller and smaller. Stock had a huge run up, and got really overvalued. They put out a great set of results on Friday. ROE is still above 30%, and is trading at about 18X 2016 earnings. The stock had a correction and then stabilized at the $6.50-$7 level, and he thinks the stock is going to start to advance. Emerging as a nice, high quality stock.

Show full opinionHide full opinion
BioSyent Inc (RX-X)
March 7, 2016

Had been built around a single product that related to iron deficiency. They have taken fairly high levels of profitability and have been picking up other stuff, and a lot of those other drugs have taken time to get a sales channel. Now that we are into 2016, those other products are starting to contribute, so the dependency on a single drug is getting smaller and smaller. Stock had a huge run up, and got really overvalued. They put out a great set of results on Friday. ROE is still above 30%, and is trading at about 18X 2016 earnings. The stock had a correction and then stabilized at the $6.50-$7 level, and he thinks the stock is going to start to advance. Emerging as a nice, high quality stock.

PAST TOP PICK
PAST TOP PICK
December 23, 2015

(A Top Pick Dec 24/14. Down 31.61%.) Great company. Share price has not performed very well. They have delivered great results since then, but we have seen all this multiple contraction in the healthcare sector. Fairly narrowly focused around 1 drug. Its value is starting to get to the point where people are going to start to nibble. Be patient.

Show full opinionHide full opinion
BioSyent Inc (RX-X)
December 23, 2015

(A Top Pick Dec 24/14. Down 31.61%.) Great company. Share price has not performed very well. They have delivered great results since then, but we have seen all this multiple contraction in the healthcare sector. Fairly narrowly focused around 1 drug. Its value is starting to get to the point where people are going to start to nibble. Be patient.

PAST TOP PICK
PAST TOP PICK
October 19, 2015

(A Top Pick Dec 24/14. Down 31.71%.) This stock came down early in the year because of concerns about their over focus on a single product. Corrected earlier in the year and has just been trading sideways. Looks cheap. He expects it will bounce back with the rest of the sector.

Show full opinionHide full opinion
BioSyent Inc (RX-X)
October 19, 2015

(A Top Pick Dec 24/14. Down 31.71%.) This stock came down early in the year because of concerns about their over focus on a single product. Corrected earlier in the year and has just been trading sideways. Looks cheap. He expects it will bounce back with the rest of the sector.

BUY
BUY
June 30, 2015

Would rate this as a Buy, but not a strong Buy. He is comfortable that they can grow their profits over the next 3 years by 25%-30% per year. However, this company is narrowly focused on 1 or 2 products, and they need to diversify beyond that. He thinks they will get there. A good name to own at the $7.50-$8 level.

Show full opinionHide full opinion
BioSyent Inc (RX-X)
June 30, 2015

Would rate this as a Buy, but not a strong Buy. He is comfortable that they can grow their profits over the next 3 years by 25%-30% per year. However, this company is narrowly focused on 1 or 2 products, and they need to diversify beyond that. He thinks they will get there. A good name to own at the $7.50-$8 level.

PAST TOP PICK
PAST TOP PICK
May 11, 2015

(A Top Pick June 4/14. Up 15.41%.) This is smallish and conservative, but continues to improve its numbers. Continues to get its products, mostly iron related, into pharmacies all across Canada. He is confident they can continue to increase their product range.

Show full opinionHide full opinion
BioSyent Inc (RX-X)
May 11, 2015

(A Top Pick June 4/14. Up 15.41%.) This is smallish and conservative, but continues to improve its numbers. Continues to get its products, mostly iron related, into pharmacies all across Canada. He is confident they can continue to increase their product range.

BUY
BUY
May 6, 2015

The issue with this is that it is too dependent on a single product. When people started realizing how much of their earnings came from one product, it made him nervous. As it overshot up into that $11-$12 range, it got really extended. It has now checked back and he would rate it is a Buy again. He is pretty comfortable that over the next 2-3 years it will grow its top line and its bottom line at 30% per annum for the next 3 years. They now have a whole bunch of other new products that they have already launched and are starting to ramp up.

Show full opinionHide full opinion

The issue with this is that it is too dependent on a single product. When people started realizing how much of their earnings came from one product, it made him nervous. As it overshot up into that $11-$12 range, it got really extended. It has now checked back and he would rate it is a Buy again. He is pretty comfortable that over the next 2-3 years it will grow its top line and its bottom line at 30% per annum for the next 3 years. They now have a whole bunch of other new products that they have already launched and are starting to ramp up.

BUY
BUY
March 24, 2015

Very steady, careful accumulator of products to market in Canada in the medical field.

Show full opinionHide full opinion
BioSyent Inc (RX-X)
March 24, 2015

Very steady, careful accumulator of products to market in Canada in the medical field.

WEAK BUY
WEAK BUY
February 23, 2015

Likes the story but the valuation is a bit too high. It is not that liquid of a stock. Hard to buy in a fund, but okay for individual investors. Prefers MLS-T.

Show full opinionHide full opinion
BioSyent Inc (RX-X)
February 23, 2015

Likes the story but the valuation is a bit too high. It is not that liquid of a stock. Hard to buy in a fund, but okay for individual investors. Prefers MLS-T.

Showing 1 to 15 of 21 entries

BioSyent Inc(RX-X) Rating

Ranking : 1 out of 5

Bullish - Buy Signals / Votes : 0

Neutral - Hold Signals / Votes : 0

Bearish - Sell Signals / Votes : 0

Total Signals / Votes : 0

Stockchase rating for BioSyent Inc is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

BioSyent Inc(RX-X) Frequently Asked Questions

What is BioSyent Inc stock symbol?

BioSyent Inc is a Canadian stock, trading under the symbol RX-X on the TSX Venture Exchange (RX-CV). It is usually referred to as TSXV:RX or RX-X

Is BioSyent Inc a buy or a sell?

In the last year, there was no coverage of BioSyent Inc published on Stockchase.

Is BioSyent Inc a good investment or a top pick?

BioSyent Inc was recommended as a Top Pick by Jason Del Vicario on 2018-04-12. Read the latest stock experts ratings for BioSyent Inc.

Why is BioSyent Inc stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is BioSyent Inc worth watching?

0 stock analysts on Stockchase covered BioSyent Inc In the last year. It is a trending stock that is worth watching.

What is BioSyent Inc stock price?

On 2020-09-30, BioSyent Inc (RX-X) stock closed at a price of $7.